Development asset linked to Dr. Ferrer BioPharma in public FDA and regional records.
pharma · Progressive supranuclear palsy (PSP) · Amyotrophic Lateral Sclerosis
Dr. Ferrer BioPharma
Ferrer Internacional S.A.
Dr. Ferrer BioPharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hallandale Beach, USA HQ
2020 Founded
11 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Hallandale Beach, USA
- Founded
- 2020
- Employees
- 11
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Dr. Ferrer BioPharma pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dr. Ferrer BioPharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
pridopidine
Nervous system (N07)Nervous system (N07) compound in Dr. Ferrer BioPharma's portfolio. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor modulator